U.S. Markets closed

ChromaDex Corporation (CDXC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.6700+0.0100 (+0.21%)
At close: 4:00PM EST
Sign in to post a message.
  • C
    CS
    Can't link, but Tru Niagen is now available via Watson's World-- wider Asian distribution?

    A.S. Watson Group is excited to announce the rollout of Watsons World, a one-stop shopping site that offers the world's best health & beauty items. Customers can now shop the Tourist’s’ Top Picks curated by local experts, and have them delivered right to their doorstep.

    Shop without borders at Watsons World

    https://www.youtube.com/watch?v=VDgLRuh2ISo

    Search Watsons World via UTube link :

    >> "We use NAD+ every day for basic functions like sleeping, breathing, eating, and drinking. But as our body ages, it becomes more difficult to maintain our cognitive and physical health. Tru Niagen® gives our body the extra power it requires to raise our NAD+ levels, strengthen cellular immunity, revive our cells and restore our youthful energy and vigor.

    No worries if you can’t find them in local stores. Check out worldwide exclusive offers in Watsons World and join us for a SHOPCATION!

    Watsons World is a one-stop shopping site that offers the world’s best health & beauty items with free Asia delivery. (Free Asia shipping for orders US$60 or above.) You can shop for tourists’ favorites in different regions in the same site with no-fuss."
  • s
    stefan_001
    the results will be interesting. Sales look up compared to previous Q when scanning the various Amazon sites. The TN site is also looking cleaner and ordering process easier.
  • J
    Jeff Manzanita
    https://www.businesstimes.com.sg/life-culture/life-extension-–-health-rejuvenation-and-longevity

    The article is more likely to lead people to buy NMN than NR, since NMN is mentioned more. Some readers might pay attention to the comment about NR having better access to the cells.
  • b
    bryan
    If you purchased shares of CDXC back in 2008, you would be down 50% 13-years later. Fortunately, most of us have only owned shares for the past 1-5 years and during that time have been able to trade it so that we have been able to profit from the experience. But this is suppose to be a growth stock. We should be able to make money from this company engaging in a Buy and Hold strategy. We should not have to trade this thing like a cyclical company. So what's the problem here??? It's not the product. It's management.

    What are we paying these people for??? Frank Jaksch gets $600k/year to be Exec. Chairman....what is the board doing to improve shareholder value?

    Alberto Bottene - Sr. VP Sales.....has this guy closed any sales for the company?

    Megan Kern Jordan - Sr. VP Marketing.....what marketing? We have not seen anything of significance to market TruNiagen.

    Ben Shichman - Chief Technology Officer.....what does this even mean for our company? Would be fantastic if he was building a mobile platform or similar type of program that would engage our current customers, provide additional value to them and serve as a means to help them share and spread the word about TruNiagen. BUT WE DO NOT HAVE ANYTHING OF THE SORT.

    Will Black - Consultant....would seem like he has told everyone at the company to just sleep and stay silent and do nothing.

    The CFO and our Chief Legal person I think are earning their salaries and are doing their best. But what is everyone else doing for us? We see nothing, we hear nothing, and thus we have a stock that does nothing. Yet we keep paying millions and millions of dollars in salaries and stock options to these people.

    Hey, maybe they are all very hard at work on exciting projects that will finally propel the company to new heights, but why not share this with us shareholders? We don't need to be told the specifics. Keep it vague if necessary. But this silence is insulting. Although, not as insulting as being paid to give us quarter after quarter of slowing growth and blaming it on our partners or saying you have no idea why sales are slowing. That is downright criminal!
  • b
    bryan
    All the good news regarding the science or partnerships or anything else we have had in the past has all resulted in the exact same outcome: an immediate jump in share price followed by a steady sell-off that erases the gains. The reason for this is simple. The CEO does not believe in marketing, sales people or PR. He has no clue how to generate hype, sell TruNiagen, build a brand, create customer loyalty, market a consumer health product or advertise. He thinks the current customers will handle all this for him via W.O.M. word-of-mouth. This is insanity. That is why sales growth has continued to diminish quarter to quarter. The only growth he is able to generate for the company is when he cuts off another partner so he can take some of their customers away. This however generates another enemy for the company and additional legal headaches and expenses. IF YOU WANT TO SEE THE SHARE PRICE ABOVE $10, IT WILL REQUIRE ACCELERATING SALES GROWTH FROM QUARTER TO QUARTER. Our current customers may love the product, but they don't care or have any loyalty to the company. Chromadex has done nothing to create a loyal customer base. Chromadex has done nothing to add value to the customer experience. Chromadex has done nothing towards creating a platform that would allow customers to generate hype and build awareness. The CEO has no experience with any of this, doesn't even understand how to even begin creating or building what is necessary to accomplish this. He doesn't even know to hire people that can do any of this. Until us shareholders create enough outrage over his poor track record, we will be doomed holding a stock that goes nowhere. Fried is like a sea anchor holding back the S.S. Chromadex from even leaving port. If you don't agree with me, then you have not owned this stock long enough....give it a couple more years and you'll change your mind. Till then, if you want to make any money from this thing, I recommend trading it...buy/cover between $4-4.50 and sell/short it between $5.25-5.75.
  • M
    Marshmallow
    Insta pun dit dott comm
    Jan 13 2021
    "FASTER, PLEASE: Researchers identify promising model for studying human aging. Declining muscle mass and function is something that can be addressed, at least in part, by exercise, and perhaps supplements like niagen."
    Posted at 7:00 pm by Glenn Reynolds
  • I
    Ig
    Celltrient is 20% off on amzn, bringing the cost of a 14 pack down from $35 to $28...
    It’s currently rated a whopping 163,005 in health and household.
  • M
    Michael
    It won’t let me post the link but search: “ Australian Pharmacies gain access to NAD+ Supplement Tru Niagen”
  • J
    Jeff Manzanita
    This was posted on Shelly's Chromadex Retail Investors Facebook site:

    https://raisingnad.com/harvard-alzheimers-expert-explains-why-i-religiously-take-tru-niagen/?fbclid=IwAR3YvRPs9HC3qhlSmdn_1ZzIejKC_IPY2gvI-KZLIXkds8tp5P-hVCpknns

    That Dr. Tanzi discusses NR regarding Alzheimers is not news to us, that it is being considered regarding treatment for people who are experiencing the lingering effects of COVID is new to me. There are people who have "recovered" from COVID 6 months ago who still struggle from its effects, including damaged brain function. This may be the greatest benefit of NR regarding COVID, especially since we still are without adequate trial results, and the roll out of vaccinations to prevent new infections is accelerating.
    In a mid-November podcast appearance, Harvard neuroscientist and Alzheimer’s expert Dr Rudy Tanzi made a compelling case for supplementing with Nicotinamide Riboside (NR) / TRU Niagen. This week, he joined “The New 100 Longevity Campaign” program and
    In a mid-November podcast appearance, Harvard neuroscientist and Alzheimer’s expert Dr Rudy Tanzi made a compelling case for supplementing with Nicotinamide Riboside (NR) / TRU Niagen. This week, he joined “The New 100 Longevity Campaign” program and
    raisingnad.com
  • T
    Tony
    Cdxc just released a lot of TN commercial on their yooo tube channel a few hours ago.
  • j
    jr.raines
    This is to funny - I joined Robinhood to see what kids are buying (RIOT is in top 100). They give you a free share when you join. My free share was OPKO - $4.66
  • C
    C
    Very quiet. Random user @scott said he was accumulating under 5 based on a source. Probably a bot but I hope the level of silenced is matched by the level of importance of the next PR.
    Bullish
  • I
    Ig
    Wow...looks like GRA more likely than not will get sold, and perhaps for more than the $4.3B ($65/share) recently offered.
  • C
    CS
    Doctor Creates Anti Aging Supplement Stack For ELON MUSK
    1,615 views •Jan 13, 2021

    Dr. Brad Stanfield

    #5 ~ 4:30

    https://www.youtube.com/watch?v=7utXMFySvHI&feature=youtu.be
  • E
    Ezra
    Ig’s great NR story now up at RaisingNAD. So many great stories here lately. Thank you Ig!
  • C
    CS
    Third party analysis, reads like CDXC dropped the ball...

    How Two Recent Court Decisions Show Ownership Can Be Everything and Standing Must Be Taken Into Account

    >> Take-Away
    In the U.S., initially inventorship determines ownership. But ownership rights may be subject to contracts and laws. Care must be taken to not overlook language that may result in a loss of patent rights. This may come in an internal portfolio review, in a due diligence situation, or, as in these cases, litigation. And we see in ChromaDex, it is important to verify standing before an exclusive licensee brings an action for patent infringement.

    https://www.finnegan.com/en/insights/blogs/prosecution-first/how-two-recent-court-decisions-show-ownership-can-be-everything-and-standing-must-be-takeninto-account.html
  • C
    CS
    Robert Fried, CEO ChromaDex, Academy Award winning Producer Rudy and Godzilla

    2 views•Jan 12, 2021

    https://www.youtube.com/watch?v=edbu2KBFd2c
  • C
    CS
    EH 2020 Year-in-review--

    >> 2021 Preview: In the Pipeline

    Just as we partnered with Dr. Guarente at MIT to develop Basis, Dr. Levine at Yale to develop Index, and Dr. Smith at Oxford to develop Matter, we'll soon be announcing a partnership with another renowned healthcare institution with which we’re working to develop our next product — launching in 2021.

    https://milled.com/elysium-health/elysium-year-in-review-partnerships-with-oxford-and-yale-and-more-F7VE7MC4eCOnlFsx
  • C
    C
    Can’t believe no news at all. With everything going on in the background. More news comes from Ezra than the company itself!
  • M
    Michael
    THE NEW 100 LONGEVITY CAMPAIGN- EP5 “STOPPING ALZHEIMER’S DISEASE IN ITS TRACKS” interview with Rockstar Scientist Dr. Rudy Tanzi:

    https://www.google.com/amp/s/amp.flipboard.com/@hostlindacooper/stopping-alzheimer-s-the-cure-prevention-ep5-the-new-100-longevity-campaign-1pg6iqvqf2uu0sno